| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 66.900 +8.26% on 06/10/26 | | 82.000 -11.68% on 06/01/26 | -6.575 (-8.32%) since 05/22/26 |
| 3-Month | 62.000 +16.81% on 04/02/26 | | 92.000 -21.28% on 05/11/26 | +3.425 (+4.96%) since 03/20/26 |
| 52-Week | 28.000 +158.66% on 07/02/25 | | 92.000 -21.28% on 05/11/26 | +39.925 (+122.85%) since 06/20/25 |
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational...
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the...
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer...
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer ® and pre|CISION™ platforms, announces that the US Food and...
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer ® and pre|CISION™ platforms,...
| 3rd Resistance Point | 78.100 |
| 2nd Resistance Point | 76.550 |
| 1st Resistance Point | 75.100 |
| Last Price | 72.425 |
| 1st Support Level | 72.100 |
| 2nd Support Level | 70.550 |
| 3rd Support Level | 69.100 |
| 52-Week High | 92.000 |
| Last Price | 72.425 |
| Fibonacci 61.8% | 67.552 |
| Fibonacci 50% | 60.000 |
| Fibonacci 38.2% | 52.448 |
| 52-Week Low | 28.000 |